Can you take Epoprostenol with Tekturna?
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- epoprostenol
- Tekturna (aliskiren)
Drug interactions
Moderate drug interactions
Moderate:
epoprostenol aliskiren
Applies to: epoprostenol and Tekturna (aliskiren)
Using epoprostenol together with aliskiren may have additive effects in lowering your blood pressure.
You may experience:
- dizziness
- lightheadedness
- fainting
- flushing
- headache
- a rapid pulse or heart rate
These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption.
Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. You may need a dose adjustment or more frequent monitoring to safely use both medications.
Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
aliskiren Food/Lifestyle
Applies to: Tekturna (aliskiren)
Food can affect the absorption of aliskiren from the intestine.
Therefore, you should take aliskiren at the same time each day exactly as prescribed by your doctor. You may take aliskiren with or without food, but take it the same way every time. This will help keep blood levels and effects of the medication steady.
You should avoid drinking orange, apple, or grapefruit juice as much as possible during treatment with aliskiren. Studies have shown that drinking these juices regularly or within a short period before or after a dose of aliskiren can interfere with the absorption of the medication.
Disease interactions
9 potential interactions Applies to: 8 conditions, including Heart Failure, Diabetes Mellitus, Hyponatremia, Bleeding Disorder, and Dehydration.
Bleeding Disorder
Moderate:
epoprostenol
Epoprostenol has a moderate potential interaction with Bleeding Disorder.
Epoprostenol is a potent inhibitor of platelet aggregation. Therefore, expect an increased risk for hemorrhagic complications, particularly for patients with other risk factors for bleeding. Caution and close monitoring is advised.
Cerebral Thrombosis/Embolism
Moderate:
epoprostenol
Epoprostenol has a moderate potential interaction with Cerebral Thrombosis/Embolism.
Epoprostenol is a potent inhibitor of platelet aggregation. Therefore, expect an increased risk for hemorrhagic complications, particularly for patients with other risk factors for bleeding. Caution and close monitoring is advised.
Dehydration
Moderate:
Tekturna
The aliskiren in Tekturna has a moderate potential interaction with Dehydration.
Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system. It is recommended to correct the volume or salt depletion before administering aliskiren. Close monitoring is recommended.
Diabetes Mellitus
Major:
Tekturna
The aliskiren in Tekturna has a major potential interaction with Diabetes Mellitus.
The use of aliskiren is contraindicated in patients with diabetes who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), as there is an increased risk of renal impairment, hyperkalemia, and hypotension.
Heart Failure
Major:
epoprostenol
Epoprostenol has a major potential interaction with Heart Failure.
The use of epoprostenol is contraindicated in patients with heart failure due to reduced severe left ventricular systolic dysfunction. A large study involving such patients was terminated after an interim analysis revealed a higher mortality in the group receiving epoprostenol plus standard therapy than in the group receiving standard therapy alone.
Moderate:
Tekturna
The aliskiren in Tekturna has a moderate potential interaction with Heart Failure.
Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure. Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure. Treatment should be discontinued in any patients who develop clinically significant decrease in renal function. Patients with renal impairment should be observed closely. The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.
History - Myocardial Infarction
Moderate:
Tekturna
The aliskiren in Tekturna has a moderate potential interaction with History - Myocardial Infarction.
Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure. Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure. Treatment should be discontinued in any patients who develop clinically significant decrease in renal function. Patients with renal impairment should be observed closely. The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.
Hyponatremia
Moderate:
Tekturna
The aliskiren in Tekturna has a moderate potential interaction with Hyponatremia.
Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system. It is recommended to correct the volume or salt depletion before administering aliskiren. Close monitoring is recommended.
Renal Dysfunction
Moderate:
Tekturna
The aliskiren in Tekturna has a moderate potential interaction with Renal Dysfunction.
Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure. Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure. Treatment should be discontinued in any patients who develop clinically significant decrease in renal function. Patients with renal impairment should be observed closely. The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.
Report options
More resources
epoprostenol
A total of 311 drugs are known to interact with epoprostenol.
- Epoprostenol is in the drug class agents for pulmonary hypertension.
- Epoprostenol is used to treat Pulmonary Arterial Hypertension.
Tekturna
A total of 319 drugs are known to interact with Tekturna.
- Tekturna is in the drug class renin inhibitors.
- Tekturna is used to treat High Blood Pressure.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.